- Home
- GOF vs AGIO Comparison
GOF vs AGIO Comparison
Compare GOF & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOF
- AGIO
- Stock Information
- Founded
- GOF 2006
- AGIO 2007
- Country
- GOF United States
- AGIO United States
- Employees
- GOF N/A
- AGIO N/A
- Industry
- GOF Finance/Investors Services
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- GOF Finance
- AGIO Health Care
- Exchange
- GOF Nasdaq
- AGIO Nasdaq
- Market Cap
- GOF 2.3B
- AGIO 2.5B
- IPO Year
- GOF N/A
- AGIO 2013
- Fundamental
- Price
- GOF $11.99
- AGIO $24.46
- Analyst Decision
- GOF
- AGIO Buy
- Analyst Count
- GOF 0
- AGIO 7
- Target Price
- GOF N/A
- AGIO $37.33
- AVG Volume (30 Days)
- GOF 789.2K
- AGIO 1.8M
- Earning Date
- GOF 01-01-0001
- AGIO 10-30-2025
- Dividend Yield
- GOF 15.42%
- AGIO N/A
- EPS Growth
- GOF N/A
- AGIO N/A
- EPS
- GOF N/A
- AGIO N/A
- Revenue
- GOF N/A
- AGIO $44,791,000.00
- Revenue This Year
- GOF N/A
- AGIO $25.57
- Revenue Next Year
- GOF N/A
- AGIO $153.24
- P/E Ratio
- GOF N/A
- AGIO N/A
- Revenue Growth
- GOF N/A
- AGIO 36.26
- 52 Week Low
- GOF $10.96
- AGIO $22.24
- 52 Week High
- GOF $16.76
- AGIO $62.45
- Technical
- Relative Strength Index (RSI)
- GOF 25.63
- AGIO 25.59
- Support Level
- GOF $11.96
- AGIO $22.24
- Resistance Level
- GOF $13.35
- AGIO $46.00
- Average True Range (ATR)
- GOF 0.28
- AGIO 2.20
- MACD
- GOF -0.08
- AGIO -1.86
- Stochastic Oscillator
- GOF 0.85
- AGIO 8.76
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.